Influence of dosing vehicles on the preclinical pharmacokinetics of phenolic antioxidants

Research Communications in Molecular Pathology and Pharmacology

Volumn 104, Issue 1, 1999, Pages 93-106

  Vora, Jayesh ^a,c   Wu, Zheng ^b,c   Montague, Monica ^c   Penn, Michael ^c   Erow, Kevin ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BUTLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIOXIDANT; BUTYLATED HYDROXYANISOLE; DIMETHYL SULFOXIDE; GALLIC ACID PROPYL ESTER; PHENOL DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BUTYLATED HYDROXYANISOLE; HUMANS; INJECTIONS, INTRAPERITONEAL; LIVER; MICE; PROPYL GALLATE; RATS; RATS, SPRAGUE-DAWLEY; VEHICLES;

EID: 0032705729     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Boxenbaum, H. and Ronfeld, R. (1983). Interspecies pharmacokinetic scaling and the Dedrick plots. Am. J. Physiol. 245: R678-R774.
2. th edition, Edited by Miller, S.E., Williams & Wilkins, Baltimore, MD, USA, pp. 316.
3. Corte, L.D., Bianchi, L., Valoti, M., and Sgaragli, G. (1989). Distribution and peroxidative oxidation of 2-t-butyl-4-methoxyphenol in rat tissues after a single intraperitoneal dose. J. Biochem. Toxicol. 4: 147-150.
4. Daoud, A.H. and Griffin, A.C. (1985). Effect of retinoic acid, butylated hydroxytoluene, propyl gallate and selenium on 2-acetylaminofluorene induced hepatotoxicity. Cancer Lett. 29: 183-188.
5. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10: 1093-1095.
6. El-Rashidy, R. and Niazi, S. (1980). Comparative pharmacokinetics of butylated hydroxyanisole and butylated hydroxytoluene in rabbits. J. Pharm. Sci. 69: 1455-1457.
7. Gibaldi, M and Perrier, D. (1982). Pharmacokinetics, 2nd edition, Marcel Dekker, New York, NY, USA.
8. Gorsdorf, S., Appel, K.E., Obe, G., and Hildebrandt, A.G. (1987). Inhibition of bleomycin-induced DNA strand breaks in V79 Chinese hamster cells by the antioxidant propyl gallate. 3: 135-143.
9. Hirose, M., Yada, H., Hakoi, K., Takahashi, S., and Ito, N. (1993). Modification of carcinogenesis by alpha-tocopherol, t-butylhydroquinone, propyl gallate, and butylated hydroxytoluene in a rat multi-organ carcinogenesis model. Carcinogenesis 14: 2359-2364.
10. th edition, McGraw Hill, New York, NY, USA, pp. 386.
11. Kachmar, J.R. (1976). Enzymes. In: Fundamentals of Clinical Chemistry. Edited by Tietz, N.W. Saunders, Philadelphia, PA, USA, pp. 674.
12. 1 metabolism. Carcinogenesis 18: 1729-1738.
13. Nedelman, J.R., Gibiansky, E., and Lau, D.T.W. (1995). Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm. Res. 12: 124-128.
14. Singletary, K.W. (1990). Effect of dietary butylated hydroxytoluene on the in vivo distribution, metabolism and DNA-binding of 7,12-dimethylbenz(a)anthracene. Cancer Lett. 49: 187-193.
15. Talalay, P. (1989). Mechanisms of induction of enzymes that protect against chemical carinogenesis. Adv. Enzyme Regul. 28: 237-250.
16. Tamano, S., Fukushima, S., Shirai, T., Hirose, M., and Ito, N. (1987). Modification by alpha-tocopherol, propyl gallate, and tertiary butylhydroquinone of urinary bladder carcinogenesis in Fischer 344 rats pretreated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Lett. 35: 39-45.
17. Uekama, K., and Otagiri, M. (1987). Cyclodextrins in drug carrier systems. CRC Crit. Rev. Ther. Drug Carrier Sys. 3: 1-40.
18. Verhagen, H., Thijssen, H.H.W., Ten Hoor, F., Kleinjans, J.C.S. (1989). Disposition of single oral doses of butylated hydroxyanisole in man and rat. Food. Chem. Toxic. 27: 151-158.
19. Verhagen, H., Beckers, H.H.G., Comuth, P.A.W.V., Maas, L.M., Ten Hoor, F., Henderson, P.T., Kleinjas, J.C.S. (1989). Disposition of single oral doses of butylated hydroxytoluene in man and rat. Fd. Chem. Toxic. 27: 765-772.
20. Vora, J. and Boroujerdi, M. (1995). Enhanced aqueous solubility of phenolic antioxidants using modified β-cyclodextrins. Drug Develop. Ind. Pharm. 21: 495-502.
21. Vora, J., Khaw, B.A., Narula, J., and Boroujerdi, M. (1996). Protective effect of butylated hydroxyanisole in adriamycin-induced carditoxicity in rats. J. Pharm. Pharmacol. 48: 940-944.
22. Vora, J. and Boroujerdi, M. (1996). Pharmacokinetic-toxicodynamic relationships of adrimaycin in the rat - Prediction of butylated hydroxyanisole mediated reduction in anthracycline cardiotoxicity. J. Pharm. Pharmacol. 48: 1264-1269.
23. Whysner, J. and Williams, G.M. (1996). Butylated hydroxyanisole mechanistic data and risk assessment: Conditional species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol. Therap. 71: 137-151.